CY1123365T1 - Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα - Google Patents
Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεαInfo
- Publication number
- CY1123365T1 CY1123365T1 CY20201100912T CY201100912T CY1123365T1 CY 1123365 T1 CY1123365 T1 CY 1123365T1 CY 20201100912 T CY20201100912 T CY 20201100912T CY 201100912 T CY201100912 T CY 201100912T CY 1123365 T1 CY1123365 T1 CY 1123365T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- beta2
- adrenorector
- muscarinic receptor
- receptor antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε ενώσεις του γενικού τύπου Ι, οι οποίες δρουν και ως ανταγωνιστές μουσκαρινικού υποδοχέα και ως αγωνιστές βήτα2 αδρενεργικού υποδοχέα, σε μεθόδους για την παρασκευή αυτών, σε συνθέσεις που περιλαμβάνουν αυτές, σε θεραπευτικές χρήσεις και συνδυασμούς με άλλα φαρμακευτικά δραστικά συστατικά.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195891 | 2012-12-06 | ||
| EP13811827.8A EP2928889B1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| PCT/EP2013/075661 WO2014086924A1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123365T1 true CY1123365T1 (el) | 2021-12-31 |
Family
ID=47323975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100469T CY1120159T1 (el) | 2012-12-06 | 2018-05-03 | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα |
| CY20201100912T CY1123365T1 (el) | 2012-12-06 | 2020-09-28 | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100469T CY1120159T1 (el) | 2012-12-06 | 2018-05-03 | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8987299B2 (el) |
| EP (2) | EP3345904B1 (el) |
| JP (1) | JP6421989B2 (el) |
| KR (2) | KR102156443B1 (el) |
| CN (1) | CN104822678B (el) |
| AR (1) | AR093825A1 (el) |
| AU (1) | AU2013354043C1 (el) |
| BR (1) | BR112015012730B1 (el) |
| CA (1) | CA2893626C (el) |
| CL (1) | CL2015001483A1 (el) |
| CO (1) | CO7400870A2 (el) |
| CY (2) | CY1120159T1 (el) |
| DK (2) | DK3345904T3 (el) |
| EA (1) | EA030552B1 (el) |
| ES (2) | ES2816210T3 (el) |
| GE (1) | GEP20186839B (el) |
| HR (2) | HRP20180915T1 (el) |
| HU (2) | HUE037944T2 (el) |
| IL (1) | IL239182B (el) |
| LT (2) | LT2928889T (el) |
| MA (1) | MA38147B1 (el) |
| MX (1) | MX369311B (el) |
| NZ (1) | NZ708738A (el) |
| PE (1) | PE20151216A1 (el) |
| PH (1) | PH12015501247B1 (el) |
| PL (2) | PL2928889T3 (el) |
| PT (2) | PT3345904T (el) |
| RS (2) | RS57232B1 (el) |
| SA (1) | SA515360514B1 (el) |
| SG (2) | SG11201504318UA (el) |
| SI (2) | SI2928889T1 (el) |
| TN (1) | TN2015000244A1 (el) |
| TR (1) | TR201808698T4 (el) |
| TW (1) | TWI637954B (el) |
| UA (1) | UA118181C2 (el) |
| WO (1) | WO2014086924A1 (el) |
| ZA (1) | ZA201503965B (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| BR112015012730B1 (pt) * | 2012-12-06 | 2022-07-05 | Chiesi Farmaceutici S.P.A. | Composto, composição farmaceutica, dispositivo, uso de um composto e combinação |
| RU2661877C2 (ru) | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| HK1215166A1 (zh) | 2012-12-18 | 2016-08-19 | Almirall, S.A. | 具有β2肾上腺素激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| DK3377108T3 (da) * | 2015-11-16 | 2020-04-20 | Chiesi Farm Spa | Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum |
| EP3383867B1 (en) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA2994290C (en) | 2017-11-06 | 2024-01-23 | Entech Solution As | Method and stimulation sleeve for well completion in a subterranean wellbore |
| CN116635370A (zh) * | 2020-12-21 | 2023-08-22 | 英特维特国际股份有限公司 | 制备n-(双(4-甲氧基苯基)甲基)-6-氧代-2-(哒嗪-3-基)-1,6-二氢嘧啶-5-甲酰胺的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2222128A (en) | 1937-01-29 | 1940-11-19 | Pure Oil Co | Preparation and separation of aromatic hydrocarbons |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| BR0315234A (pt) | 2002-10-11 | 2005-08-23 | Pfizer | Derivados de indol como agonistas beta-2 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CN100569760C (zh) | 2003-11-21 | 2009-12-16 | 施万制药 | 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物 |
| PT1708992E (pt) | 2004-01-22 | 2007-11-16 | Pfizer | Derivados de sulfonamida para o tratamento de doenças |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| AP2315A (en) | 2004-03-23 | 2011-11-04 | Pfizer | Formamide derivatives useful as adrenoceptor. |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| FR2898640B1 (fr) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| DK2599778T3 (en) | 2009-04-23 | 2017-06-26 | Theravance Respiratory Co Llc | Diamide compounds with muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activity |
| SG177468A1 (en) * | 2009-04-30 | 2012-02-28 | Teijin Pharma Ltd | Quaternary ammonium salt compound |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| PE20141614A1 (es) * | 2011-06-10 | 2014-11-20 | Chiesi Farma Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico |
| RU2606121C2 (ru) | 2011-06-10 | 2017-01-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| BR112015012730B1 (pt) * | 2012-12-06 | 2022-07-05 | Chiesi Farmaceutici S.P.A. | Composto, composição farmaceutica, dispositivo, uso de um composto e combinação |
-
2013
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt not_active IP Right Cessation
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh not_active Expired - Fee Related
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko not_active Expired - Fee Related
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en not_active Ceased
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active Active
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en not_active Ceased
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja not_active Expired - Fee Related
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 HR HRP20180915TT patent/HRP20180915T1/hr unknown
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
-
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247B1/en unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
-
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
-
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123365T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| EA201401351A1 (ru) | Производные бензимидазол-пролина | |
| CY1116892T1 (el) | Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
| EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| EA201490037A1 (ru) | Антагонисты trpv4 | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
| UA111640C2 (uk) | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| BR112015012746A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| EA201270741A1 (ru) | Пероральные композиции и липофильные соли метилналтрексона | |
| EA201500628A1 (ru) | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| EA201400822A1 (ru) | Производные гетероциклических амидов в качестве антагонистов p2xрецептора | |
| EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| EA201001842A1 (ru) | Новые соединения, обладающие активностью антагонистов мускариновых рецепторов | |
| EA201590452A1 (ru) | СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ | |
| UA112586C2 (uk) | Похідні бензімідазолпроліну | |
| UA109581C2 (uk) | Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2 | |
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |